Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes
Executive Summary
Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.
You may also be interested in...
Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.
Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile
Merck & Co and Pfizer release new combo data for their investigational SGLT2 inhibitor at the ADA – combinations will be key to the latecomer's overall success.
Novo Nordisk Sharpens Its Outlook But Warns Risks Remain Later In 2017
A robust first quarter allowed the Danish diabetes fighter to tighten its guidance - but things are likely to get bumpier for the troubled group as the year progresses.